We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise Intervention Study for Pancreatic Cancer Patients (SUPPORT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01977066
Recruitment Status : Completed
First Posted : November 6, 2013
Last Update Posted : February 27, 2017
Sponsor:
Collaborators:
University of Heidelberg Medical Center
Deutsche Krebshilfe e.V., Bonn (Germany)
Information provided by (Responsible Party):
German Cancer Research Center

Brief Summary:
The purpose of this study is to compare the effects of two specific exercise interventions and one standard care control arm on physical functioning.The investigators expect that supervised training is most beneficial to the patients. However, they also expect some benefit for patients in the home-based training.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Behavioral: Six months supervised resistance training Behavioral: Six months home-based exercise training Not Applicable

Detailed Description:

The randomized-controlled balanced-parallel-group trial included 65 adult pancreatic cancer patients (stage I-IV) from the University Surgery Clinic in Heidelberg. The study compared two specific exercise interventions and one standard care control arm. The intervention programs were (1) a 6-month supervised moderate-to-high-intensity, progressive resistance training, and (2) a 6-month home-based exercise training. Thus, the two interventions differed primarily by the intensity and mode-of-administration of the intervention. Both interventions started at the earliest 8 weeks after surgery to allow for wound healing until Maximum 12 months after the surgery. The supervised progressive training started with only moderate-intensity training during the first 4 weeks. Only patients without comorbidities that preclude participation in the intervention arms (e.g. severe pain, heart insufficiency, reduced standing or walking ability) were eligible.

The primary objective is to compare the effects of the different interventions on physical functioning, measured as change from baseline to 6 months. Additional endpoints are overall quality of life, fatigue, endurance, and strength performance, adherence to the interventions, discontinuation of adjuvant therapy, body weight and composition, disease progression, overall and progression-free survival. All outcomes has been assessed every 3 months for a minimum follow-up period of 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: SUPPORT - Study Supervised Progressive Resistance Training for Pancreatic Cancer Patients: a Randomized Controlled Intervention Trial
Study Start Date : November 2013
Actual Primary Completion Date : June 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Six months supervised exercise training Behavioral: Six months supervised resistance training
progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.

Experimental: Six months home-based exercise training Behavioral: Six months home-based exercise training
Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.

No Intervention: Control group



Primary Outcome Measures :
  1. Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30 [ Time Frame: Change from baseline to end of intervention (after 6 months) ]

Secondary Outcome Measures :
  1. Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26) [ Time Frame: change from Baseline to end of intervention (6 months) ]

Other Outcome Measures:
  1. Fatigue (Multidimensional Fatigue Inventory (MFI)) [ Time Frame: change from baseline to end of intervention (6 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pancreatic cancer patients (stage I-IV)
  • Patients ≥ 18 years of age
  • Resection performed at the University Clinic of Heidelberg
  • Sufficient German language skills
  • Signed informed consent

Exclusion Criteria:

• Presence of comorbidities that preclude participation in the intervention arms (e.g. severe pain, heart insufficiency, reduced standing or walking ability)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01977066


Locations
Layout table for location information
Germany
German Cancer Research Center
Heidelberg, Germany, D-69120
Sponsors and Collaborators
German Cancer Research Center
University of Heidelberg Medical Center
Deutsche Krebshilfe e.V., Bonn (Germany)
Investigators
Layout table for investigator information
Principal Investigator: Karen G Steindorf, Prof. Dr. German Cancer Research Center (DKFZ)/ German National Center for Tumor Diseases (NCT)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: German Cancer Research Center
ClinicalTrials.gov Identifier: NCT01977066    
Other Study ID Numbers: SUPPORT
First Posted: November 6, 2013    Key Record Dates
Last Update Posted: February 27, 2017
Last Verified: February 2017
Keywords provided by German Cancer Research Center:
pancreatic cancer
exercise training
quality of life
physical functioning
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases